Oragenics Inc is a biotechnology company focused on the development and licensure of innovative products and technologies for improving human health.
| Revenue (Most Recent Fiscal Year) | $0.04M |
| Net Income (Most Recent Fiscal Year) | $-10.57M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.29 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -571.79% |
| Return on Assets (Trailing 12 Months) | -216.07% |
| Current Ratio (Most Recent Fiscal Quarter) | 4.42 |
| Quick Ratio (Most Recent Fiscal Quarter) | 4.42 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $-0.51 |
| Earnings per Share (Most Recent Fiscal Quarter) | -- |
| Earnings per Share (Most Recent Fiscal Year) | -- |
| Diluted Earnings per Share (Trailing 12 Months) | $-11.97 |
| Exchange | NYSEMKT |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 4.27M |
| Free Float | 4.06M |
| Market Capitalization | $2.94M |
| Average Volume (Last 20 Days) | 0.12M |
| Beta (Past 60 Months) | 1.13 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 4.90% |
| Percentage Held By Institutions (Latest 13F Reports) | 18.71% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |